Get the Stockscreener App
48.31
2.79%
1.31
After Hours:
48.31
Merus N V Stock (MRUS) Latest News
US Bancorp DE Lowers Holdings in Merus (NASDAQ:MRUS) - Defense World
Merus (NASDAQ:MRUS) Given “Buy” Rating at Guggenheim - Defense World
Merus (NASDAQ:MRUS) Given Average Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Given New $70.00 Price Target at Bank of America - Defense World
Why Merus Shares Are Facing Pressure Today - TipRanks
Merus (NASDAQ:MRUS) Short Interest Down 13.5% in February - Defense World
Stifel maintains Buy on Merus stock with $93 target By Investing.com - Investing.com Australia
Stifel maintains Buy on Merus stock with $93 target - Investing.com
Merus N.V. Reports 2024 Earnings and Clinical Progress - TipRanks
Need To Know: The Consensus Just Cut Its Merus N.V. (NASDAQ:MRUS) Estimates For 2025 - Simply Wall St
Merus (NASDAQ:MRUS) Receives “Buy” Rating from HC Wainwright - Defense World
Merus stock holds Buy rating and $85 target from H.C. Wainwright - Investing.com India
Merus stock holds Buy rating and $85 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Needham & Company LLC Cuts Merus (NASDAQ:MRUS) Price Target to $83.00 - Defense World
Merus’ (MRUS) Outperform Rating Reiterated at William Blair - Defense World
Earnings Update: Merus N.V. (NASDAQ:MRUS) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts - Simply Wall St
Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates - MSN
Analyst Forecasts Just Became More Bearish On Merus N.V. (NASDAQ:MRUS) - Yahoo Canada Finance
Merus (NASDAQ:MRUS) Posts Quarterly Earnings Results, Beats Estimates By $0.48 EPS - MarketBeat
BMO Capital lifts Merus stock target to $96, maintains Outperform By Investing.com - Investing.com South Africa
BMO Capital lifts Merus stock target to $96, maintains Outperform - Investing.com
Merus Shares Soar Amid Breakthrough Therapy Hopes - TipRanks
Merus NV reports results for the quarter ended December 31Earnings Summary - TradingView
Merus N.V. Updates on Petosemtamab Trials and Financial Outlook for 2025 and Beyond - Nasdaq
Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update - GlobeNewswire
Merus Secures FDA Approval for Cancer Drug With $724M War Chest to Fund Operations Through 2028 - StockTitan
Merus N.V. SEC 10-K Report - TradingView
Merus N.V. to Host Earnings Call - ACCESS Newswire
Investor Network: Merus N.V. to Host Earnings Call - ACCESS Newswire
State of New Jersey Common Pension Fund D Buys 10,842 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus to Present at Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Oncology Innovator Merus Schedules Two Major Investor Presentations - StockTitan
Merus (MRUS) to Release Quarterly Earnings on Wednesday - MarketBeat
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
TimesSquare Capital Management LLC Purchases 58,760 Shares of Merus (NASDAQ:MRUS) - MarketBeat
Merus Stock Soars on Cancer Treatment Breakthrough - TipRanks
La FDA américaine a accordé le statut de thérapie innovante au pétosemtamab dans le carcinome épidermoïde de la tête et du cou positif PD-L1 positif en 1re ligne - GlobeNewswire Inc.
Merus Shares Are Up Today: What's Going On?Merus (NASDAQ:MRUS) - Benzinga
Merus Stock Surges on Breakthrough Therapy News - TipRanks
Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab -February 18, 2025 at 09:00 am EST - Marketscreener.com
Objective long/short (MRUS) Report - Stock Traders Daily
Petosemtamab granted Breakthrough Therapy designation by - GlobeNewswire
Revolutionary Cancer Treatment: 67% Response Rate Earns FDA Breakthrough Status for Head & Neck Cancer Drug - StockTitan
Merus (NASDAQ:MRUS) Now Covered by Analysts at Piper Sandler - MarketBeat
Merus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trials - MSN
0.22%
0.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):